One of Australia’s largest industry funds has lifted its venture capital allocation to $100 million, ignoring fears about ...

After decades of hype and setbacks, scientists have made impressive progress into tricking stem cells into repairing organs.

The use of stereotactic body radiotherapy (SBRT) as salvage therapy after radical prostatectomy was well tolerated, with no ...

GlobalData analysts have tipped the global market for genomic therapies to balloon to almost $90 billion by 2030, driven by ...

President Donald Trump's executive order on drug pricing may threaten Roche's planned $50 billion investment in the U.S. By ...

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

Analysts are still crunching the numbers on the impact of President Donald Trump's executive order from Monday on drug pricing. HSBC analyst Rajesh Kumar says a 20% price cut in government channels ...

Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid ...

Global pharmaceutical shares are slumping Monday after President Donald Trump said he is looking to slash the price of ...

Shares of global pharma stocks slumped on Monday after President Trump vowed to cut drug prices for Americans by as much as 80%.

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...